Menopause Practice Questions

Q: What is the most common cause of postmenopausal bleeding?

Endometrial atrophy. **Explanation:** **1. Why Endometrial Atrophy is Correct:** Endometrial atrophy is the **most common cause** of postmenopausal bleeding (PMB), accounting for approximately 60–80% of cases. In the postmenopausal state, low estrogen levels lead to a thin, friable endometrial lining. The lack of structural support causes the thin epithelium to shed or the underlying microvasculature to rupture easily, resulting in light spotting or bleeding. **2. Analysis of Incorrect Options:** * **Endometrial Cancer (A):** While this is the most **concerning** cause that must be ruled out, it accounts for only about 10% of PMB cases. * **Endometrial Polyps (B):** These are common benign growths and a frequent cause of PMB (approx. 10–15%), but they are less common than atrophy. * **Endometrial Hyperplasia (D):** This is a precursor to malignancy caused by unopposed estrogen. While significant, it is statistically less frequent than atrophic changes. **3. Clinical Pearls for NEET-PG:** * **Gold Standard Investigation:** Fractional Curettage (historically) or Office Endometrial Biopsy (Pipelle). * **First-line Screening:** Transvaginal Ultrasound (TVUS). * **Cut-off Value:** An endometrial thickness (ET) of **≤ 4 mm** in a postmenopausal woman has a high negative predictive value for malignancy. If ET is > 4 mm, a biopsy is mandatory. * **Most common cause of PMB worldwide:** Endometrial Atrophy. * **Most common gynecological malignancy in developed countries:** Endometrial Cancer (In India, it is traditionally Cervical Cancer, though Endometrial Cancer is rising in urban populations).

Q: Hot flushes are observed due to deficiency of?

Estrogen. **Explanation:** **1. Why Estrogen is the Correct Answer:** Hot flushes (vasomotor symptoms) are the most common symptom of the perimenopausal and menopausal transition. They occur due to the **decline in circulating estrogen levels**. Estrogen plays a critical role in stabilizing the **thermoregulatory center** in the hypothalamus. When estrogen levels drop, the "thermostat" becomes hypersensitive, narrowing the thermoneutral zone. This leads to an exaggerated heat-dissipation response (peripheral vasodilation and sweating) even with minor changes in core body temperature. **2. Why Other Options are Incorrect:** * **Progesterone:** While progesterone levels also decline during menopause, its primary role is in endometrial regulation. Progesterone withdrawal does not trigger the hypothalamic thermoregulatory dysfunction responsible for hot flushes. * **Testosterone:** Androgen levels decline gradually with age (senescence) rather than abruptly at menopause. Deficiency is more closely linked to decreased libido and muscle mass, not vasomotor instability. * **Cortisol:** Cortisol is a stress hormone produced by the adrenal cortex. Its deficiency (Addison’s disease) causes hypotension and electrolyte imbalances, not menopausal hot flushes. **3. NEET-PG High-Yield Pearls:** * **Most common symptom of menopause:** Hot flushes (75-80% of women). * **Hormonal Hallmark:** Decreased Estrogen + **Increased FSH** (FSH >40 IU/L is diagnostic of menopause). * **Mechanism:** Narrowing of the "Thermoreutral Zone" in the hypothalamus. * **Treatment of Choice:** Hormone Replacement Therapy (HRT) with Estrogen is the most effective treatment for vasomotor symptoms. * **Non-hormonal alternative:** SSRIs (e.g., Paroxetine) or Gabapentin are used if HRT is contraindicated.

Q: Hormone replacement therapy in post-menopausal women increases the risk of all the following conditions EXCEPT:

Colorectal cancer. **Explanation:** The question focuses on the findings of the **Women’s Health Initiative (WHI) trial**, which redefined the risks and benefits of Hormone Replacement Therapy (HRT). **Why Colorectal Cancer is the correct answer:** HRT (specifically combined Estrogen and Progesterone) has a **protective effect** against colorectal cancer. Large-scale clinical trials demonstrated a significant reduction (approximately 30-40%) in the incidence of colorectal cancer among women using combined HRT. Therefore, it does not increase the risk; it decreases it. **Analysis of Incorrect Options:** * **Breast Cancer:** Long-term use of combined HRT (Estrogen + Progestogen) is associated with an increased risk of breast cancer. This risk is primarily linked to the progestogen component. * **Stroke:** HRT increases the risk of ischemic stroke. This is part of the overall cardiovascular risk profile associated with oral estrogen therapy in older post-menopausal women. * **Thromboembolism:** Oral estrogen increases the synthesis of clotting factors in the liver (first-pass effect), leading to a 2-to-3-fold increased risk of **Deep Vein Thrombosis (DVT)** and **Pulmonary Embolism**. **NEET-PG High-Yield Pearls:** 1. **Endometrial Cancer:** Unopposed estrogen therapy increases the risk of endometrial cancer; hence, Progesterone is always added if the uterus is intact. 2. **Fracture Risk:** HRT is highly effective in reducing the risk of **osteoporotic fractures** (hip and spine). 3. **Lipid Profile:** HRT typically increases HDL and decreases LDL, but it also increases **Triglycerides**. 4. **Gallstones:** HRT increases the risk of cholelithiasis due to increased cholesterol saturation of bile. 5. **Window of Opportunity:** HRT is safest when started within 10 years of menopause or before age 60.

Q: A 48-year-old female with severe dysfunctional uterine bleeding (DUB) underwent hysterectomy and wishes to take hormone replacement therapy. Physical examination, including breast examination, is normal, but X-ray shows osteoporosis. What is the treatment of choice?

Estrogen. ### **Explanation** The core principle in Hormone Replacement Therapy (HRT) is determining the presence of a uterus. **1. Why Estrogen is the Correct Answer:** The patient has undergone a **hysterectomy**. In women without a uterus, **Estrogen-only therapy (ERT)** is the treatment of choice. Estrogen effectively manages vasomotor symptoms and is highly effective in preventing and treating **osteoporosis** (as seen in this patient) by inhibiting osteoclast activity and reducing bone resorption. Since the uterus has been removed, there is no risk of estrogen-induced endometrial hyperplasia or carcinoma. **2. Why Other Options are Incorrect:** * **Progesterone (A):** Progesterone is not used as a standalone therapy for postmenopausal symptoms or osteoporosis. Its primary role in HRT is to protect the endometrium. * **Estrogen and Progesterone (B):** This "Combined HRT" is mandatory for women with an **intact uterus**. Adding progesterone to this specific patient is unnecessary and increases the risk of breast cancer and cardiovascular side effects without any clinical benefit, as she no longer has an endometrium to protect. * **None (D):** Treatment is indicated because the patient is symptomatic and has radiographic evidence of osteoporosis. ### **Clinical Pearls for NEET-PG:** * **Gold Standard for Osteoporosis:** While HRT is effective, **Bisphosphonates** are the first-line non-hormonal treatment for osteoporosis. However, if a postmenopausal woman is also symptomatic, HRT is an excellent choice. * **The "Uterus Rule":** * Uterus Present = Estrogen + Progesterone (to prevent endometrial CA). * Uterus Absent = Estrogen Only. * **Contraindications to HRT:** Undiagnosed vaginal bleeding, estrogen-dependent tumors (Breast/Endometrial CA), active thromboembolism (DVT/PE), and chronic liver disease. * **Window of Opportunity:** HRT is most beneficial when started within 10 years of menopause or before age 60.

Q: Which of the following is a common symptom indicated in menopausal women?

Hot flash. **Explanation:** **Correct Answer: A. Hot flash** Menopause is defined by the permanent cessation of menstruation due to the loss of ovarian follicular activity, leading to a profound decline in **estrogen** levels. This estrogen deficiency affects the thermoregulatory center in the hypothalamus (via increased neurokinin B and altered serotonin/norepinephrine levels), resulting in **vasomotor symptoms (VMS)**. Hot flashes are the most common and characteristic symptom of menopause, affecting approximately 75–85% of women. **Analysis of Incorrect Options:** * **B. Breast cancer:** While the risk of breast cancer increases with age and prolonged exposure to hormones (HRT), it is a pathological condition (malignancy), not a physiological symptom of menopause. * **C. Endometriosis:** This is an estrogen-dependent condition. Since estrogen levels drop significantly during menopause, endometriosis typically regresses or improves after the climacteric. * **D. Uterine bleeding:** Menopause is defined by 12 months of amenorrhea. Any vaginal bleeding occurring after menopause is considered **Post-Menopausal Bleeding (PMB)** and is a red flag that must be investigated to rule out endometrial carcinoma. **NEET-PG High-Yield Pearls:** 1. **Most common symptom:** Hot flashes (Vasomotor symptoms). 2. **Earliest sign of perimenopause:** Shortening of the follicular phase (decreased cycle length). 3. **Hormonal Hallmark:** Elevated **FSH >40 IU/L** is the most sensitive diagnostic marker for menopause. 4. **Treatment of choice:** Hormone Replacement Therapy (HRT) is the gold standard for vasomotor symptoms. If HRT is contraindicated, **SSRIs/SNRIs** or the newer **NK3 receptor antagonists (Fezolinetant)** are used.

Q: What is the average age of menopause?

51 years. **Explanation:** **1. Understanding the Correct Answer (D):** Menopause is defined retrospectively as the permanent cessation of menstruation following the loss of ovarian follicular activity, confirmed after 12 consecutive months of amenorrhea. Globally, and specifically in Western data frequently cited in standard textbooks (like Williams Gynecology), the **average age of menopause is 51 years**. This timing is genetically predetermined and is primarily dictated by the depletion of the ovarian follicle pool. **2. Analysis of Incorrect Options:** * **A (45 years):** While menopause can occur at 45, it is considered early. Menopause occurring between ages 40–45 is termed "Early Menopause." * **B & C (47 & 49 years):** Although the average age of menopause in Indian women is often cited as slightly lower (around 47–48 years) in regional studies, for the purpose of standardized national exams like NEET-PG, the globally accepted standard of **51 years** remains the definitive answer unless "Indian context" is specifically mentioned. **3. High-Yield Clinical Pearls for NEET-PG:** * **Premature Ovarian Insufficiency (POI):** Menopause occurring before the age of **40 years**. * **Determinants:** The age of menopause is **not** affected by the age of menarche, number of pregnancies, lactation, or use of oral contraceptives. * **Smoking:** This is the most significant modifiable factor; it can accelerate follicular depletion and shift menopause **1–2 years earlier**. * **Hormonal Profile:** The hallmark of menopause is a significant **rise in FSH (>40 IU/L)** and a decrease in Estradiol (<20 pg/mL). FSH is the most sensitive diagnostic marker. * **First Sign:** The earliest clinical sign of approaching menopause (perimenopause) is usually a **shortening of the follicular phase** (shorter menstrual cycles).

Q: Which of the following is NOT a side effect of progesterone in hormone replacement therapy?

Leg cramps. **Explanation:** In Hormone Replacement Therapy (HRT), progesterone is primarily added to estrogen to prevent endometrial hyperplasia and carcinoma in women with an intact uterus. Understanding its side-effect profile is crucial for NEET-PG. **1. Why Leg Cramps is the Correct Answer:** Leg cramps are a classic side effect associated with **Estrogen** therapy, not progesterone. Estrogen can cause fluid retention and changes in electrolyte balance, leading to muscle cramps. In contrast, progesterone has a mild diuretic effect (antimineralocorticoid action), making it an unlikely cause of leg cramps. **2. Analysis of Incorrect Options (Progesterone Side Effects):** * **Acne:** Progesterone (especially synthetic progestins derived from 19-nortestosterone) has androgenic activity, which stimulates sebaceous glands, leading to acne and oily skin. * **Irritability:** Progesterone and its metabolites (like allopregnanolone) act on GABA receptors in the brain. While they often have a sedative effect, they can cause "PMS-like" symptoms, including irritability, mood swings, and depression in sensitive individuals. * **Constipation:** Progesterone acts as a smooth muscle relaxant. By reducing the motility of the gastrointestinal tract, it increases transit time, leading to constipation. **Clinical Pearls for NEET-PG:** * **The "Gold Standard" for Menopause:** HRT is the most effective treatment for vasomotor symptoms (hot flashes). * **Progesterone Requirement:** If a woman has undergone a hysterectomy, estrogen-only therapy (ERT) is given. Progesterone is *only* added if the uterus is present to protect the endometrium. * **Other Progesterone Side Effects:** Breast tenderness (mastalgia), bloating, and breakthrough bleeding. * **Metabolic Impact:** Progestins can sometimes negate the beneficial effects of estrogen on the lipid profile (by decreasing HDL).

Q: What is the average age range for attaining menopause?

45 - 55 years. **Explanation:** **1. Understanding the Correct Answer (Option B):** Menopause is defined as the permanent cessation of menstruation due to the loss of ovarian follicular activity, clinically diagnosed after 12 consecutive months of amenorrhea. Globally, the average age of menopause is approximately **51 years**, with a normal range typically spanning from **45 to 55 years**. In the Indian context, studies often suggest a slightly earlier onset (mean age ~47–48 years), but the standard medical textbook range remains 45–55 years. **2. Analysis of Incorrect Options:** * **Option A (40–50 years):** While some women enter menopause in their early 40s, the bulk of the population transitions later. Cessation of menses before age 40 is pathologically classified as **Premature Ovarian Insufficiency (POI)**. * **Option C & D (55–68 years):** These ranges are significantly higher than the biological norm. Menopause occurring after age 55 is termed **Late Menopause**, which is a risk factor for endometrial and breast cancer due to prolonged estrogen exposure. **3. High-Yield NEET-PG Clinical Pearls:** * **Premature Menopause:** Occurs before age 40. * **Early Menopause:** Occurs between ages 40 and 45. * **First Sign of Impending Menopause:** Shortening of the follicular phase (leading to a shorter menstrual cycle). * **Best Biochemical Marker:** Elevated **FSH levels >40 IU/L** (due to loss of negative feedback from inhibin and estrogen). * **Smoking:** The only significant lifestyle factor proven to lower the age of menopause by approximately 1.5 to 2 years. * **Genetics:** The age of menopause is primarily genetically determined; it is not affected by the age of menarche, number of pregnancies, or use of oral contraceptives.

Q: Which clinical sign indicates the onset of menopause?

An increase in plasma FSH levels. **Explanation:** The transition to menopause is characterized by the depletion of ovarian follicles. As the number of viable follicles decreases, there is a significant decline in the production of **Inhibin B** and **Estradiol**. Due to the loss of negative feedback on the hypothalamic-pituitary-ovarian (HPO) axis, the anterior pituitary increases the secretion of **Follicle-Stimulating Hormone (FSH)**. * **Why Option B is correct:** An elevated serum FSH level (typically **>40 IU/L**) is the most reliable biochemical marker for menopause. It is the earliest and most significant hormonal change observed during the climacteric period. **Analysis of Incorrect Options:** * **Option A:** Menopause is defined as the *permanent cessation* of menses (amenorrhea for 12 consecutive months), not the onset of menses. * **Option C:** Corpora lutea are formed after ovulation. In menopause, anovulation is the rule due to follicular depletion; therefore, corpora lutea are absent, not excessive. * **Option D:** Cornified (superficial) cells in a vaginal smear are a sign of estrogenic activity. In menopause, the lack of estrogen leads to a predominance of **basal and parabasal cells**, resulting in an atrophic smear. **NEET-PG High-Yield Pearls:** * **Earliest hormonal change:** Decrease in Inhibin B. * **Most sensitive diagnostic marker:** Elevated FSH (FSH > LH). * **Estrogen status:** Estradiol (E2) levels fall (<20 pg/ml), and **Estrone (E1)** becomes the predominant estrogen (derived from peripheral conversion of androstenedione in adipose tissue). * **Average age:** 50–51 years in the West; approximately 47–48 years in India.

Question 1

What is the best treatment for senile vaginitis?

Accepted Answer

Hormone Replacement Therapy (HRT) + Local estrogen cream

Answer

Hormone Replacement Therapy (HRT)

Answer

Local estrogen cream

Answer

Surgery

Question 2

What is the most common cause of postmenopausal bleeding?

Accepted Answer

Endometrial atrophy

Answer

Endometrial cancer

Answer

Endometrial polyps

Answer

Endometrial hyperplasia

Question 3

Hot flushes are observed due to deficiency of?

Accepted Answer

Estrogen

Answer

Progesterone

Answer

Testosterone

Answer

Cortisol

Question 4

Hormone replacement therapy in post-menopausal women increases the risk of all the following conditions EXCEPT:

Accepted Answer

Colorectal cancer

Answer

Breast cancer

Answer

Stroke

Answer

Thromboembolism

Question 5

A 48-year-old female with severe dysfunctional uterine bleeding (DUB) underwent hysterectomy and wishes to take hormone replacement therapy. Physical examination, including breast examination, is normal, but X-ray shows osteoporosis. What is the treatment of choice?

Accepted Answer

Estrogen

Answer

Progesterone

Answer

Estrogen and progesterone

Answer

None

Question 6

Which of the following is a common symptom indicated in menopausal women?

Accepted Answer

Hot flash

Answer

Breast cancer

Answer

Endometriosis

Answer

Uterine bleeding

Question 7

What is the average age of menopause?

Accepted Answer

51 years

Answer

45 years

Answer

47 years

Answer

49 years

Question 8

Which of the following is NOT a side effect of progesterone in hormone replacement therapy?

Accepted Answer

Leg cramps

Answer

Acne

Answer

Irritability

Answer

Constipation

Question 9

What is the average age range for attaining menopause?

Accepted Answer

45 - 55 years

Answer

40 - 50 years

Answer

55 - 60 years

Answer

58 - 68 years

Question 10

Which clinical sign indicates the onset of menopause?

Accepted Answer

An increase in plasma FSH levels

Answer

The onset of menses near age 50

Answer

An excessive presence of corpora lutea

Answer

An increased number of cornified cells in the vagina

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?